Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

81.24B

Market cap81.24B

Price-Earnings ratio

19.14

Price-Earnings ratio19.14

Dividend yield

0.48%

Dividend yield0.48%

Average volume

542.42K

Average volume542.42K

High today

$789.96

High today$789.96

Low today

$774.92

Low today$774.92

Open price

$781.18

Open price$781.18

Volume

702.74K

Volume702.74K

52 Week high

$859.34

52 Week high$859.34

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

With a market cap of 81.24B, Regeneron(REGN) trades at $789.45. The stock has a price-to-earnings ratio of 19.14 and currently yields dividends of 0.48%.

As of 2026-09-18, Regeneron(REGN) stock has fluctuated between $774.92 and $789.96. The current price stands at $789.45, placing the stock +1.9% above today's low and -0.1% off the high.

Regeneron(REGN) shares are trading with a volume of 702.74K, against a daily average of 542.42K.

In the last year, Regeneron(REGN) shares hit a 52-week high of $859.34 and a 52-week low of $541.00.

REGN News

Simply Wall St 9h

How Investors Are Reacting To Regeneron Pharmaceuticals Stock Trial Disclosure Lawsuits

Regeneron Pharmaceuticals is facing federal securities class action lawsuits filed in September 2026 that allege misleading disclosures about the Phase III Fian...

TipRanks 2d

Regeneron’s ROXI-EVEREST Trial Puts a New Stroke Drug in the Spotlight

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals, Inc. is advancing a late-stage heart study cal...

MarketWatch 2d

Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

...

Analyst ratings

60%

of 30 ratings

Buy

60%

Hold

33.3%

Sell

6.7%

More REGN News

Simply Wall St 2d

Is Regeneron Pharmaceuticals Still Undervalued After The Class Action Lawsuits?

Advertisement Why the Regeneron Pharmaceuticals lawsuits matter for investors Regeneron Pharmaceuticals (REGN) is under pressure after multiple law firms laun...

TipRanks 7d

Regeneron and Sanofi Complete Key Dupilumab Itch Study, Expanding Dermatology Upside

Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. Regeneron (REGN) and Sanofi (SNYNF) have completed a Phas...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.